Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant dataStella G. Muthuri, Elga Mayo-Montero, Barbara Bertisch et al.|The Lancet Respiratory Medicine|2014Cited by 648
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*Jennifer Tom, Fang Cai, Min Bao et al.|Critical Care Medicine|2021Cited by 42
Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus InfectionSudhir Venkatesan, Dragan Mikić, Puja Myles et al.|The Journal of Infectious Diseases|2019Cited by 37
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)Iván O. Rosas, Min Bao, Norbert Bräu et al.|EClinicalMedicine|2022Cited by 37
Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort studySonsoles Salto‐Alejandre, Silvia Jiménez‐Jorge, Núria Sabé et al.|PLoS ONE|2021Cited by 22